|
|
News for:
|
|
For this drug, our server compiled this detailed Chemical Profile.
You will land on a page at the National Library of Medicine where you can drill down to consumer info, research citations, product labelling, toxicology and more. FindingHealthOnline is the world's leading health-pharma search portal and decision engine. It helps you drill down to very detailed information without interference from commercial sites that now dominate Bing, Google, and Yahoo. Near the top of our pages, you will find a link to content that best matches your query.
|
|
|
|
Click the Chemical Profile link above for detailed information.
Visit Betterchem's Drug Index for
- Exclusivity
Patents and market exclusivity
- Drug Information
Prescribing and other
information
- DMFs
Type 2 drug master files
- Databases
Free access to database search
- 21 CFR
FDA regulations for this drug
- Federal Register
FR search results for this drug
- Drug Recalls
For Rx's using this API
|
|
|
| |
FDA Approval Activities for this Drug
Lescol Capsules & Lescol XL (fluvastatin sodium) Extended release Tablets, Novartis Pharmaceutical NDA 20-261/S32 & 21-192/S4 9/6/02 9/11/02 9/6/02
Lescol XL (fluvastatin sodium) Extended release Tablets, Novartis Pharmaceutical NDA 21-192 10/6/00 10/20/00
Lescol XL (fluvastatin sodium) Extended release Tablets, Novartis Pharmaceutical NDA 21-192/S2 9/25/01 5/1/03
Lescol (fluvastatin sodium) capsules, Novartis Pharmaceutical NDA 20-261/S-018 & S-022 3/8/99 6/3/99
Lescol Supplement-018provides for a new indication, the reduction of triglycerides and ApoB in patients with primary hypercholesterolemia and mixed dyslipidemia
Lescol Supplement-022provides for a reduction in the recommended frequency of Liver Function Testing (LFT) and eliminates periodic, i.e.,
semi-annual, LFT monitoring
Lescol (fluvastatin sodium) Capsules, Novartis Pharmaceutical NDA 20-261/S-024 10/23/00 11/27/00 11/27/00
Lescol Supplement-024 as an adjunct to diet to reduce elevated total cholesterol (total-C), LDL-C, TG, and Apo B levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Frederickson Type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures has not been adequate |
Lescol (fluvastatin) Capsules, Novartis Pharmaceutical NDA 20-261/S-025 12/19/00 2/20/01 |
Lescol (fluvastatin) Capsules, Novartis Pharmaceutical NDA 20-261/S-30 | Lescol (fluvastatin sodium) Capsules, Novartis Pharma, Labeling Revision | Lescol XL (fluvastatin sodium) Extended-Release Tablets
Visit Betterchem's Drug Index for FDA's latest approval information.
|
|